Mycophenolate mofetil for the treatment of cutaneous lichen planus: A retrospective case series - 10/03/21

Funding sources: None. |
|
Disclosure: Dr Feldman has received research, speaking, and/or consulting support from a variety of companies, including Galderma, GlaxoSmithKline/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, AbbVie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation; is the founder and majority owner of www.DrScore.com; and is the founder and part owner of Causa Research, a company dedicated to enhancing patients' adherence to treatment. Authors Hrin and Bashyam and Dr Huang have no conflicts of interest to declare. |
|
IRB approval status: Reviewed and approved by Wake Forest University Health Sciences (IRB00065234). |
Vol 84 - N° 4
P. 1091-1094 - avril 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?